HomeCompareQCXGF vs JNJ

QCXGF vs JNJ: Dividend Comparison 2026

QCXGF yields 1365.19% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QCXGF wins by $298822034.25M in total portfolio value
10 years
QCXGF
QCXGF
● Live price
1365.19%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298822034.28M
Annual income
$261,186,648,013,879.53
Full QCXGF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — QCXGF vs JNJ

📍 QCXGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQCXGFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QCXGF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QCXGF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QCXGF
Annual income on $10K today (after 15% tax)
$116,040.96/yr
After 10yr DRIP, annual income (after tax)
$222,008,650,811,797.60/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, QCXGF beats the other by $222,008,650,807,811.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QCXGF + JNJ for your $10,000?

QCXGF: 50%JNJ: 50%
100% JNJ50/50100% QCXGF
Portfolio after 10yr
$149411017.15M
Annual income
$130,593,324,009,284.47/yr
Blended yield
87.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

QCXGF
No analyst data
Altman Z
4.9
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QCXGF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQCXGFJNJ
Forward yield1365.19%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$298822034.28M$30.3K
Annual income after 10y$261,186,648,013,879.53$4,689.40
Total dividends collected$296055184.59M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QCXGF vs JNJ ($10,000, DRIP)

YearQCXGF PortfolioQCXGF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$147,219$136,518.77$10,592$272.30+$136.6KQCXGF
2$2,035,854$1,878,329.51$11,289$357.73+$2.02MQCXGF
3$26,454,041$24,275,677.50$12,123$472.89+$26.44MQCXGF
4$323,109,610$294,803,786.79$13,141$629.86+$323.10MQCXGF
5$3,710,898,270$3,365,170,987.26$14,408$846.81+$3710.88MQCXGF
6$40,091,059,516$36,120,398,366.33$16,021$1,151.60+$40091.04MQCXGF
7$407,598,672,629$364,701,238,947.34$18,122$1,588.22+$407598.65MQCXGF
8$3,901,413,421,656$3,465,282,841,943.19$20,930$2,228.20+$3901413.40MQCXGF
9$35,173,258,191,565$30,998,745,830,392.96$24,792$3,191.91+$35173258.17MQCXGF
10$298,822,034,278,854$261,186,648,013,879.53$30,274$4,689.40+$298822034.25MQCXGF

QCXGF vs JNJ: Complete Analysis 2026

QCXGFStock

QcX Gold Corp. engages in the acquisition, exploration, and development of mineral properties in Mexico. It explores for gold and volcanic massive sulphide deposits. The company holds 100% interests in the Golden Giant project that covers approximately 18,992 hectares located in the James Bay region; and Kali project covering an area of approximately 10,127 hectares located in the James Bay lowlands area of Quebec. It also has an option agreement to acquire 100% interest the Fernet property that covers an area of 4,480 hectares located in the northern Abitibi region of Quebec. The company was formerly known as First Mexican Gold Corp. and changed its name to QcX Gold Corp. in July 2020. QcX Gold Corp. was incorporated in 2007 and is headquartered in Toronto, Canada.

Full QCXGF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this QCXGF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QCXGF vs SCHDQCXGF vs JEPIQCXGF vs OQCXGF vs KOQCXGF vs MAINQCXGF vs ABBVQCXGF vs MRKQCXGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.